FY2025 Earnings Forecast for ACTU Issued By HC Wainwright

Key Points

• HC Wainwright has raised its FY2025 earnings estimate for Actuate Therapeutics to ($1.02) EPS, improving from a previous estimate of ($1.05), while maintaining a "Buy" rating and a price target of $20.00.
• Actuate Therapeutics reported a quarterly earnings loss of ($0.30) EPS, missing analysts' expectations of ($0.19) EPS in its most recent earnings release.
• Insider transactions revealed that directors purchased a total of 214,284 shares of Actuate Therapeutics stock, increasing their ownership by approximately 57.14%.

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) - Research analysts at HC Wainwright raised their FY2025 earnings estimates for shares of Actuate Therapeutics in a note issued to investors on Tuesday, September 23rd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.02) for the year, up from their prior estimate of ($1.05). HC Wainwright currently has a "Buy" rating and a $20.00 price target on the stock. HC Wainwright also issued estimates for Actuate Therapeutics' Q1 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($1.06) EPS, FY2028 earnings at ($1.05) EPS and FY2029 earnings at $0.11 EPS.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.11).

A number of other analysts have also weighed in on ACTU. Wall Street Zen raised shares of Actuate Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, September 20th. B. Riley initiated coverage on Actuate Therapeutics in a research note on Tuesday, August 26th. They set a "buy" rating and a $20.00 price target for the company. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Actuate Therapeutics presently has a consensus rating of "Buy" and an average price target of $20.33.

Actuate Therapeutics Price Performance

Shares of ACTU opened at $7.02 on Thursday. The company's fifty day simple moving average is $7.53 and its 200-day simple moving average is $7.94. Actuate Therapeutics has a twelve month low of $5.47 and a twelve month high of $11.99.

Insider Buying and Selling at Actuate Therapeutics

In other news, Director Leslie W. Kreis purchased 71,428 shares of the company's stock in a transaction dated Friday, June 27th. The shares were acquired at an average price of $7.00 per share, with a total value of $499,996.00. Following the transaction, the director owned 196,428 shares of the company's stock, valued at $1,374,996. This represents a 57.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Equity Cof Lp Bios purchased 71,428 shares of Actuate Therapeutics stock in a transaction dated Friday, June 27th. The stock was acquired at an average price of $7.00 per share, with a total value of $499,996.00. Following the acquisition, the director owned 196,428 shares in the company, valued at approximately $1,374,996. This represents a 57.14% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 214,284 shares of company stock valued at $1,499,988 in the last ninety days. Corporate insiders own 69.34% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACTU. Chicago Partners Investment Group LLC purchased a new position in shares of Actuate Therapeutics in the first quarter worth $70,000. Sfmg LLC acquired a new position in shares of Actuate Therapeutics in the first quarter valued at about $74,000. Bank of America Corp DE increased its holdings in shares of Actuate Therapeutics by 61,068.0% in the second quarter. Bank of America Corp DE now owns 15,292 shares of the company's stock valued at $93,000 after purchasing an additional 15,267 shares during the period. New York State Common Retirement Fund purchased a new position in shares of Actuate Therapeutics in the second quarter worth about $105,000. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Actuate Therapeutics by 492.6% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company's stock worth $113,000 after purchasing an additional 15,393 shares during the period.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.